Can weight loss drugs boost heart function in obese heart failure patients?
NCT ID NCT06423599
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares weight loss using semaglutide (a drug) versus a calorie-restricted diet in 100 people with obesity and heart failure with reduced ejection fraction. The goal is to see which approach better improves peak oxygen uptake, a measure of exercise capacity, after 52 weeks. Participants must be on stable heart failure medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide
What this could lead to
If successful, this could show that weight loss with semaglutide improves exercise capacity and heart function in people with obesity and heart failure.
What could go wrong
This is a mid-stage trial with only 100 participants, so results may not apply to everyone. Semaglutide can cause side effects like nausea and vomiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amager and Hvidovre Hospital University of Copenhagen
RECRUITINGCopenhagen, DK-2650, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••